Table 4.
Recurrence rate and characteristics of 46 patients with long-term follow-up.
| Recurrences at 24 months | 15 (32.6%) | |
| Recurrences at 12 months | 13 (28.2%) | |
| Characteristics | Patients with recurrences (n = 15) | Patients without recurrences (n = 31) |
| BMI > 35 | 6 (40%) | 8 (25.8%) |
| Diabetes mellitus | 3 (20%) | 8 (25.8%) |
| Smoking status | 9 (60%) | 9 (29%) |
| COPD | 4 (26.7%) | 8 (25.8%) |
| Chevrel M1-M2 | 7 (46.7%) | 9 (30%)° |
| Chevrel M3-M4 | 8 (53.3%) | 21 (70%)° |
| Chevrel W1–2 | 1 (6.7%) | 10 (32.3%) |
| Chevrel W3–4 | 14 (93.3%) | 21 (67.7%) |
| VHWG Grade 1 | 1 (6.7%) | 3 (9.7%) |
| VHWG Grade 2 | 6 (40%) | 10 (32.3%) |
| VHWG Grade 3 | 8 (53.3%) | 18 (58%) |
| ASA II | 6 (40%) | 8 (25.8%) |
| ASA III-IV | 10 (66.7%) | 23 (74.2%) |
| Bridge position | 9 (60%) | 12 (38.7%) |
| Underlay position | 4 (26.7%) | 13 (41.9%) |
| Sublay position | 2 (13.3%) | 6 (19.4%) |
| Fascial closure | 6 (40%) | 19 (61.3%) |
| Non-fascial closure | 9 (60%) | 12 (38.7%) |
| Early post-operative complications | 8 (53.3%) | 10 (32.3%) |
| Wound infection | 7 (46.7%) | 7 (22.6%) |
| Seroma | 1 (6.7%) | 1 (3.2%) |
| Skin necrosis | 0 (0.0%) | 1 (3.2%) |
| Bulging | 0 (0.0%) | 1 (3.2%) |
| Rejection | 0 (0.0%) | 1 (3.2%) |
BMI: body mass index; COPD: Chronic Obstructive Pulmonary Disease; ASA: American Society of Anesthesiologists; VHWG: modified Ventral Hernia Working Group.
°Two missing data.